| Literature DB >> 31308412 |
Marinho A Lopes1,2,3, Suejen Perani4, Siti N Yaakub4, Mark P Richardson5,4,6, Marc Goodfellow7,8,5, John R Terry7,8,5.
Abstract
Seizure onset in epilepsy can usually be classified as focal or generalized, based on a combination of clinical phenomenology of the seizures, EEG recordings and MRI. This classification may be challenging when seizures and interictal epileptiform discharges are infrequent or discordant, and MRI does not reveal any apparent abnormalities. To address this challenge, we introduce the concept of Ictogenic Spread (IS) as a prediction of how pathological electrical activity associated with seizures will propagate throughout a brain network. This measure is defined using a person-specific computer representation of the functional network of the brain, constructed from interictal EEG, combined with a computer model of the transition from background to seizure-like activity within nodes of a distributed network. Applying this method to a dataset comprising scalp EEG from 38 people with epilepsy (17 with genetic generalized epilepsy (GGE), 21 with mesial temporal lobe epilepsy (mTLE)), we find that people with GGE display a higher IS in comparison to those with mTLE. We propose IS as a candidate computational biomarker to classify focal and generalized epilepsy using interictal EEG.Entities:
Mesh:
Year: 2019 PMID: 31308412 PMCID: PMC6629665 DOI: 10.1038/s41598-019-46633-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Scheme of the data analysis procedure. (a) Electrodes were placed on the scalp of 17 individuals suffering from genetic generalized epilepsy and 21 individuals with mesial temporal lobe epilepsy. (b) EEG signals were recorded and several 20 second artifact-free segments were selected per individual. This panel displays 10 EEG channels for representative purposes though in our analysis we considered 64 EEG channels. (c) Functional networks were constructed from the EEG signals. (d) Model-generated data was obtained by placing a mathematical model on each node of the functional networks. (e) The Brain Network Ictogenicity (BNI) as a function of the global scaling factor K was measured from the model-generated data. The ictogenic spread is defined as the average slope of this curve between BNI = 0.1 and BNI = 0.9 (the dashed red line).
Figure 2Two representative Brain Network Ictogenicity (BNI) curves as a function of the global scaling factor K computed from two functional networks. The blue curve corresponds to an individual with genetic generalized epilepsy, and the red curve to an individual with mesial temporal lobe epilepsy. The standard error of the BNI is not represented as it is almost indistinguishable given the scale of the figure.
Figure 3Ictogenic Spread (IS) of the genetic generalized epilepsy (GGE) and mesial temporal lobe epilepsy (mTLE) individuals. Each marker in panels (a and b) represents the mean IS of a single individual and the error bars account for the variability of IS measured across different functional networks of different EEG segments band-pass filtered between 1 and 25 Hz. Panel (a) and (b) show the IS of mTLE and GGE subjects, respectively. In panel (a), the red markers identify left mTLE individuals, whist the orange markers correspond to right mTLE individuals. The GGE group has a larger IS than the mTLE group (p < 0.001, Mann–Whitney U test with Bonferroni-Holm correction for multiple comparisons in the two frequency bands). Panel (c) exhibits the receiver operating characteristic (ROC) curve for genetic generalized epilepsy versus mTLE subjects using the IS as a classifier. The area under the curve (AUC) is 0.85, and the optimal specificity and sensitivity are 0.86 and 0.65, respectively.
Clinical characteristics of the individuals with genetic generalized epilepsy.
| ID | Age | Gender | Syndrome | Seizure freedom | Epilepsy duration | Medication | # of 20 sec segments |
|---|---|---|---|---|---|---|---|
| GGE01 | 22 | M | JME | No | 1 | VPA | 57 |
| GGE02 | 14 | F | JME | No | 1 | LMT | 37 |
| GGE03 | 20 | F | JME | Yes* | 1 | LEV | 16 |
| GGE04 | 36 | M | JME | No | 20 | VPA | 31 |
| GGE05 | 18 | F | GTCSO | No | 1 | unknown | 20 |
| GGE06 | 37 | F | JME | Yes* | 1 | LMT | 12 |
| GGE07 | 26 | F | GTCSO | Yes* | 1 | LMT | 24 |
| GGE08 | 18 | F | JME | Yes* | 1 | LMT | 15 |
| GGE09 | 22 | F | GTCSO | No | 4 | LMT | 37 |
| GGE10 | 39 | M | GTCSO | No | 11 | LEV | 12 |
| GGE11 | 40 | M | JME | No | 32 | VPA | 5 |
| GGE12 | 21 | M | JME | No | 14 | VPA | 14 |
| GGE13 | 20 | M | JME | No | 4 | VPA, LEV | 26 |
| GGE14 | 22 | F | JME | No | 7 | LMT, LEV | 33 |
| GGE15 | 30 | F | JME | No | 23 | VPA, LEV, PER | 9 |
| GGE16 | 40 | M | JME | No | 25 | VPA | 13 |
| GGE17 | 14 | M | JME | Yes* | 1 | VPA | 3 |
Age and epilepsy duration is in years, M = male, F = female, JME = juvenile myoclonic epilepsy, GTCSO = generalized tonic clonic seizure only, VPA = valproate, LEV = levetiracetam, LMT = lamotrigine, PER = perampanel. *Seizure-free individuals had not experienced seizures from about 6 months after diagnosis.
Clinical characteristics of the individuals with mTLE.
| ID | Age | Gender | Syndrome | Seizure freedom | Epilepsy duration | Medication | # of 20 sec segments |
|---|---|---|---|---|---|---|---|
| TLE01 | 41 | F | Right mTLE | No | 17 | LMT, LEV, PER, CLB | 4 |
| TLE02 | 43 | F | Left mTLE | No | 23 | CAR, LMT | 3 |
| TLE03 | 57 | F | Left mTLE | No | 52 | LEV, CIT | 15 |
| TLE04 | 22 | M | Left mTLE | No | 6 | CAR | 14 |
| TLE05 | 34 | M | Right mTLE | No | 23 | PHB, VPA, OLA, CIT | 3 |
| TLE05 | 52 | F | Left mTLE | No | 37 | LAC, CIT, LOR | 6 |
| TLE06 | 51 | F | Left mTLE | No | 20 | LAC | 4 |
| TLE08 | 31 | M | Right mTLE | No | 6 | CAR, LEV, CLB | 8 |
| TLE09 | 48 | M | Right mTLE | No | 15 | LEV, TOP | 12 |
| TLE10 | 31 | M | Right mTLE | No | 10 | LEV, ZON, CLN | 23 |
| TLE11 | 58 | F | Left mTLE | No | 11 | TOP, CLB | 10 |
| TLE12 | 24 | M | Right mTLE | No | 2 | CAR | 25 |
| TLE13 | 25 | M | Left mTLE | No | 2 | VPA, TOP | 5 |
| TLE14 | 43 | F | Left mTLE | No | 3 | CAR | 16 |
| TLE15 | 23 | M | Right mTLE | No | 1 | ZON | 23 |
| TLE16 | 47 | M | Left mTLE | No | 32 | CAR | 23 |
| TLE17 | 57 | M | Right mTLE | No | 32 | LMT | 5 |
| TLE18 | 37 | F | Left mTLE | No | 10 | CAR | 14 |
| TLE19 | 31 | F | Left mTLE | No | 9 | LEV | 17 |
| TLE20 | 44 | F | Left mTLE | No | 43 | CAR, CLB | 22 |
| TLE21 | 52 | M | Right mTLE | No | 27 | LMT, PER | 7 |
Age is in years, M = male, F = female, LEV = levetiracetam, LMT = lamotrigine, PER = perampanel, CLB = clobazam, CAR = carbamezapine, PHB = phenobarbitone, VPA=valproate, OLA=olanzapine, CIT=citalopram, ZON=zonisamide, LAC=lacosamide, LOR=lorazepam, CLN=clonazepam, TOP=topiramate.